BREZTRI AEROSPHERE & TRELEGY ELLIPTA INHALERS
COPD Maintenance Inhalers | Pharmaceutical Export Supply from India
Cordium Pharmaceuticals Pvt Ltd supports international pharmaceutical supply enquiries for respiratory medicines, including Breztri Aerosphere and Trelegy Ellipta, subject to applicable prescription, registration, import and regulatory requirements in the destination country.
⭐ BREZTRI AEROSPHERE INHALER
Composition: Budesonide + Glycopyrrolate + Formoterol Fumarate
Breztri Aerosphere is a triple-combination maintenance inhaler containing an inhaled corticosteroid (ICS), long-acting muscarinic antagonist (LAMA), and long-acting beta2-agonist (LABA).
The current US FDA prescribing information includes Breztri for maintenance treatment of COPD and also lists a maintenance-treatment indication for asthma. The exact indication and availability can vary by market.
Key Benefits of Breztri Aerosphere
Three respiratory medicines in one inhaler
Combines anti-inflammatory and bronchodilator therapy
Designed for maintenance treatment rather than immediate rescue
Can simplify a patient's maintenance inhaler regimen
Useful for appropriate patients requiring triple therapy under medical supervision
Important Limitations / Disadvantages
Not a rescue inhaler for sudden breathing problems.
Requires correct inhaler technique and regular use.
May cause adverse effects such as oral thrush, respiratory infections, headache, cough or other medicine-specific reactions.
Corticosteroid-containing inhalers can increase the risk of oral fungal infection; rinsing the mouth after use is important.
Patients should be assessed by a healthcare professional before treatment.
It should not automatically be substituted for another triple inhaler because the active ingredients, device and approved indications differ.
TRELEGY ELLIPTA INHALER
Composition: Fluticasone Furoate + Umeclidinium + Vilanterol
Trelegy Ellipta is a single-inhaler triple therapy combining an inhaled corticosteroid (ICS), a long-acting muscarinic antagonist (LAMA) and a long-acting beta2-agonist (LABA).
In the US, Trelegy Ellipta is approved for long-term maintenance treatment of COPD. The US label also includes an adult asthma indication; however, country-specific approvals must always be checked before marketing or supply.
Trelegy Ellipta Advantages
Once-daily single-inhaler triple therapy in applicable indications
Combines three complementary respiratory medicines
Convenient single-device maintenance treatment
Used for long-term control rather than immediate relief
May help improve lung function and reduce COPD exacerbations in appropriately selected patients.
Trelegy Ellipta Disadvantages / Safety Points
Not intended to treat sudden acute bronchospasm.
It is not a replacement for a prescribed rescue inhaler when one is required.
Possible adverse effects include oral candidiasis, respiratory infections, headache, cough, dysphonia and other medicine-specific reactions.
Pneumonia is an important risk in COPD patients receiving inhaled corticosteroids.
It should not be combined with another LABA-containing medicine unless specifically directed by a healthcare professional.
Rinse the mouth with water after inhalation without swallowing.
Prescription and regulatory requirements vary by country.
🌍 INTERNATIONAL PHARMACEUTICAL SUPPLY ENQUIRIES
Cordium Pharmaceuticals Pvt Ltd welcomes enquiries from licensed distributors, hospitals, clinics, pharmacies and pharmaceutical procurement organizations, subject to destination-country regulations.
🇸🇬 Singapore
Target locations: Singapore, Jurong, Woodlands, Tampines
Search intent: Trelegy Ellipta Singapore, Trelegy inhaler Singapore, COPD inhaler Singapore, Breztri Aerosphere Singapore
🇲🇾 Malaysia
Target locations: Kuala Lumpur, Petaling Jaya, Johor Bahru, Penang
Search intent: Trelegy Ellipta Malaysia, Trelegy inhaler Malaysia, COPD inhaler Malaysia, Breztri Aerosphere Malaysia
🇰🇪 Kenya
Target locations: Nairobi, Mombasa, Kisumu, Nakuru
Search intent: Trelegy Ellipta Kenya, Trelegy inhaler Kenya, COPD inhaler Kenya, Breztri Aerosphere Kenya
🇺🇸 USA
Target locations: New York, Los Angeles, Houston, Chicago, Miami
Search intent: Trelegy Ellipta USA, Trelegy inhaler USA, Breztri Aerosphere USA, COPD inhaler USA
🇬🇧 UK
Target locations: London, Birmingham, Manchester, Glasgow, Liverpool
Search intent: Trelegy Ellipta UK, Trelegy inhaler UK, Breztri Aerosphere UK, COPD inhaler UK
🇦🇪 UAE
Target locations: Dubai, Abu Dhabi, Sharjah, Ajman
Search intent: Trelegy Ellipta UAE, Trelegy inhaler Dubai, Breztri Aerosphere UAE, COPD inhaler UAE
🇿🇦 South Africa
Target locations: Johannesburg, Cape Town, Durban, Pretoria
Search intent: Trelegy Ellipta South Africa, Trelegy inhaler South Africa, Breztri Aerosphere South Africa, COPD inhaler South Africa
CONTACT CORDIUM PHARMACEUTICALS
WhatsApp: +91-9405117673
Email: info@cordiumpharma.com
COPD Maintenance Inhalers | Pharmaceutical Export Supply from India
Cordium Pharmaceuticals Pvt Ltd supports international pharmaceutical supply enquiries for respiratory medicines, including Breztri Aerosphere and Trelegy Ellipta, subject to applicable prescription, registration, import and regulatory requirements in the destination country.
⭐ BREZTRI AEROSPHERE INHALER
Composition: Budesonide + Glycopyrrolate + Formoterol Fumarate
Breztri Aerosphere is a triple-combination maintenance inhaler containing an inhaled corticosteroid (ICS), long-acting muscarinic antagonist (LAMA), and long-acting beta2-agonist (LABA).
The current US FDA prescribing information includes Breztri for maintenance treatment of COPD and also lists a maintenance-treatment indication for asthma. The exact indication and availability can vary by market.
Key Benefits of Breztri Aerosphere
Three respiratory medicines in one inhaler
Combines anti-inflammatory and bronchodilator therapy
Designed for maintenance treatment rather than immediate rescue
Can simplify a patient's maintenance inhaler regimen
Useful for appropriate patients requiring triple therapy under medical supervision
Important Limitations / Disadvantages
Not a rescue inhaler for sudden breathing problems.
Requires correct inhaler technique and regular use.
May cause adverse effects such as oral thrush, respiratory infections, headache, cough or other medicine-specific reactions.
Corticosteroid-containing inhalers can increase the risk of oral fungal infection; rinsing the mouth after use is important.
Patients should be assessed by a healthcare professional before treatment.
It should not automatically be substituted for another triple inhaler because the active ingredients, device and approved indications differ.
TRELEGY ELLIPTA INHALER
Composition: Fluticasone Furoate + Umeclidinium + Vilanterol
Trelegy Ellipta is a single-inhaler triple therapy combining an inhaled corticosteroid (ICS), a long-acting muscarinic antagonist (LAMA) and a long-acting beta2-agonist (LABA).
In the US, Trelegy Ellipta is approved for long-term maintenance treatment of COPD. The US label also includes an adult asthma indication; however, country-specific approvals must always be checked before marketing or supply.
Trelegy Ellipta Advantages
Once-daily single-inhaler triple therapy in applicable indications
Combines three complementary respiratory medicines
Convenient single-device maintenance treatment
Used for long-term control rather than immediate relief
May help improve lung function and reduce COPD exacerbations in appropriately selected patients.
Trelegy Ellipta Disadvantages / Safety Points
Not intended to treat sudden acute bronchospasm.
It is not a replacement for a prescribed rescue inhaler when one is required.
Possible adverse effects include oral candidiasis, respiratory infections, headache, cough, dysphonia and other medicine-specific reactions.
Pneumonia is an important risk in COPD patients receiving inhaled corticosteroids.
It should not be combined with another LABA-containing medicine unless specifically directed by a healthcare professional.
Rinse the mouth with water after inhalation without swallowing.
Prescription and regulatory requirements vary by country.
🌍 INTERNATIONAL PHARMACEUTICAL SUPPLY ENQUIRIES
Cordium Pharmaceuticals Pvt Ltd welcomes enquiries from licensed distributors, hospitals, clinics, pharmacies and pharmaceutical procurement organizations, subject to destination-country regulations.
🇸🇬 Singapore
Target locations: Singapore, Jurong, Woodlands, Tampines
Search intent: Trelegy Ellipta Singapore, Trelegy inhaler Singapore, COPD inhaler Singapore, Breztri Aerosphere Singapore
🇲🇾 Malaysia
Target locations: Kuala Lumpur, Petaling Jaya, Johor Bahru, Penang
Search intent: Trelegy Ellipta Malaysia, Trelegy inhaler Malaysia, COPD inhaler Malaysia, Breztri Aerosphere Malaysia
🇰🇪 Kenya
Target locations: Nairobi, Mombasa, Kisumu, Nakuru
Search intent: Trelegy Ellipta Kenya, Trelegy inhaler Kenya, COPD inhaler Kenya, Breztri Aerosphere Kenya
🇺🇸 USA
Target locations: New York, Los Angeles, Houston, Chicago, Miami
Search intent: Trelegy Ellipta USA, Trelegy inhaler USA, Breztri Aerosphere USA, COPD inhaler USA
🇬🇧 UK
Target locations: London, Birmingham, Manchester, Glasgow, Liverpool
Search intent: Trelegy Ellipta UK, Trelegy inhaler UK, Breztri Aerosphere UK, COPD inhaler UK
🇦🇪 UAE
Target locations: Dubai, Abu Dhabi, Sharjah, Ajman
Search intent: Trelegy Ellipta UAE, Trelegy inhaler Dubai, Breztri Aerosphere UAE, COPD inhaler UAE
🇿🇦 South Africa
Target locations: Johannesburg, Cape Town, Durban, Pretoria
Search intent: Trelegy Ellipta South Africa, Trelegy inhaler South Africa, Breztri Aerosphere South Africa, COPD inhaler South Africa
CONTACT CORDIUM PHARMACEUTICALS
WhatsApp: +91-9405117673
Email: info@cordiumpharma.com
Keywords
